Micro Medical Solutions announces the compilation of a Scientific Advisory Board that includes six international leaders in the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI) to plan and carry out clinical trials and explore new treatments.
“We are excited to bring this group of highly esteemed physicians on to our Advisory Board,” says MMS Chief Medical Officer, Dr Jihad Mustapha, in a media release.
“PAD and CLI affect millions. Nearly 25% of people with CLI will undergo limb amputation, and that number continues to rise. The Scientific Advisory Board will guide current clinical studies for MicroStent and other technologies in development, helping MMS to develop new treatments that save limbs and improve lives.”
Micro Medical Solutions CEO Gregory Sullivan adds that, “The formation of the MMS Scientific Advisory Board represents an integral step in our clinical progress and strategic positioning for the future. We can now draw on the clinical experience and vision of six world leaders in PAD and CLI treatment at a critical time, as MicroStent enters a clinical study in the US and completes first-in-man cases abroad.”
Members of the MMS Scientific Advisory board are already providing guidance for international studies and a pivotal trial of MicroStent in the US. An inaugural meeting is planned for 2018, the release continues.
[Source(s): Micro Medical Solutions, Business Wire]